Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) prodrug, is used to prevent graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). Although previous studies have reported that enterohepatic circulation (EHC) of MPA, which is usually observed in MMF-treated patients, does not occur in HSCT patients, it is unclear what happens in haploidentical–HSCT (haplo-HSCT) patients, who are using post-transplant cyclophosphamide. This study was conducted to investigate MPA pharmacokinetics in haplo-HSCT patients.
Methods
Seventeen haplo-HSCT patients, who received MMF for GVHD prophylaxis, were enrolled in this study. We collected blood samples on days 14 and 28, and plasma MPA concentrations were measured by high-performance liquid chromatography; pharmacokinetic parameters such as area under the curve (AUC), mean residence time (MRT), and apparent oral clearance (CL/F) were measured with moment analysis. We also evaluated EHC as AUC6-12h/AUC0-12h.
Results
There was no significant difference in MPA pharmacokinetic parameters between days 14 and 28. There was also no difference between the pharmacokinetic parameter changes and diarrhea. Additionally, varying plasma MPA concentrations suggested that MPA EHC did not occur.
Conclusion
In this study, we revealed the pharmacokinetics of MMF in Japanese haplo-HSCT recipients. Additionally, our study demonstrated that MPA EHC might not occur in Japanese haplo-HSCT recipients.
ZhangDChowDSL.Clinical pharmacokinetics of mycophenolic acid in hematopoietic stem cell transplantation recipients. Eur J Drug Metab Pharmacokinet2017;
42: 183–189.
2.
MinagawaKYamamoriMKatayamaY, et al.
Mycophenolate mofetil: fully utilizing its benefits for GVHD prophylaxis. Int J Hematol2012;
96: 10–25.
3.
van GelderTMeurYLShawLM, et al.
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit2006;
28: 145–154.
4.
BemerMJSorrorMSandmaierBM, et al.
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic dell transplant recipients. Cancer Chemother Pharmacol2013;
72: 607–618.
5.
LuznikLO'DonnellPVSymonsHJ, et al.
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant2008;
14: 641–650.
6.
SugitaJKawashimaNFujisakiT, et al.; Japan Study Group for Cell Therapy and Transplantation.
HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant2015;
21: 1646–1652.
7.
SugitaJKagayaYMiyamotoT, et al.; Japan Study Group for Cell Therapy and Transplantation (JSCT).
Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant2019;
54: 432–441.
8.
JacobsonPRogosheskeJBarkerJN, et al.
Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther2005;
78: 486–500.
9.
GiacconeLMcCuneJSMarisMB, et al.
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood2005;
106: 4381–4388.
10.
HaentzschelIFreiberg-RichterJPlatzbeckerU, et al.
Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant2008;
42: 113–120.
11.
McDermottCLSandmaierBMStorerB, et al.
Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant2013;
19: 1159–1166.
12.
BejanyanNRogosheskeJDeForT, et al.
Higher dose of mycophenolate mofetil reduces acute graft-versus-host disease in reduced-intensity conditioning double umbilical cord transplantation. Biol Blood Marrow Transplant2015;
21: 926–933.
13.
HarnicarSPonceDMHildenP, et al.
Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft-versus-host disease after double-unit cord blood transplantation. Biol Blood Marrow Transplant2015;
21: 920–925.
14.
LiHMagerDESandmaierBM, et al.
Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biol Blood Marrow Transplant2014;
20: 1121–1129.
15.
NakanoKIwamiDYamadaT, et al.
Development of a formula to correct particle-enhanced turbidimetric inhibition immunoassay values so that it more precisely reflects high-performance liquid chromatography values for mycophenolic acid. Transplant Direct2017;
4: e337.
16.
TabataK.Moment analysis program available on microsoft excel®. Xenobio Metabol and Dispos1999;
14: 286–293.
17.
NaesensMKuyperDRJVerbekeK, et al.
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplant2006;
82: 1074–1084.
18.
KagayaHMiuraMSatohS, et al.
No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharm Ther2008;
33: 193–201.
19.
BaiyongSBingCWeixiaZ, et al.
Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor transplant recipients and deceased donor liver transplant recipients. Liver Transpl2009;
15: 1473–1480.
20.
PrzepiorkaDWeisdorfDMartinP, et al.
1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant1995;
15: 825–828.
21.
KandaY.Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant2013;
48: 452–458.
22.
YoshimuraKYanoIYamamotoT, et al.
Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant2018;
53: 44–51.
FrymoyerAVerottaDJacobsonP, et al.
Population pharmacokinetics of unbound mycophenolic acid in adult allogenic hematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol2013;
75: 463–475.
25.
KuypersDRNaesensMVermeireS, et al.
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther2005;
78: 351–361.
26.
LevesqueEDelageRBenoit-BiancamanoMO, et al.
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther2007;
81: 392–400.
27.
SaekiMSaitoYJinnoH, et al.
Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J2006;
6: 63–75.
28.
JiaoZDingJJShenJ, et al.
Population pharmacokinetic modeling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol2008;
65: 893–907.
29.
FukudaTGoebelJThogersenH, et al.
Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol2011;
51: 309–320.
30.
JohnsonHJSwanSKHeim-DuthoyKL, et al.
The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther1998;
63: 512–518.
31.
HuangHFYaoXChenY, et al.
Cyclosporine a and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration – a randomized controlled trial Chinese live related donor kidney transplant recipients. Int J Clin Pract2014;
68: 4–9.
32.
KoflerSShvetsNBigdeliAK, et al.
Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients – a prospective case-controlled study. Am J Transplant2009;
9: 1650–1656.
33.
JacobsonPEl-MassahSFRogosheskeJ, et al.
Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant2009;
44: 113–120.
34.
RoyerBLarosaFLegrandF, et al.
Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant2009;
15: 1134–1139.
35.
GerkPMVoreM.Regulation of expression of the multidrug resistance associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther2002;
302: 407–415.
36.
PayenLSparfelLCourtoisA, et al.
The drug efflux pump MR. P2 Regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol2002;
18: 221–233.
37.
ShibayamaYUshinohamaKIkedaR, et al.
Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci2006;
97: 1260–1266.
